Literature DB >> 9635896

Inhibition of NMDA-receptor mediated response in the rat medial prefrontal cortical pyramidal cells by the 5-HT3 receptor agonist SR 57227A and 5-HT: intracellular studies.

X Liang1, V L Arvanov, R Y Wang.   

Abstract

The techniques of intracellular recording and single-electrode voltage-clamp were used to study the effect of serotonin (5-HT) and the selective 5-HT3 receptor agonist SR 57227A on N-methyl-D-aspartic acid (NMDA)-evoked responses in pyramidal cells of the rat medial prefrontal cortex (mPFC) in in vitro brain slice preparations. Bath application of 5-HT or SR 57227A produced a concentration-dependent inhibition of NMDA-induced membrane depolarization, action potentials, and inward current. The depressant action of 5-HT and SR 57227A had a slow onset and showed no signs of receptor desensitization. This action was markedly attenuated or completely blocked by the selective 5-HT3 receptor antagonists granisetron and BRL 46470A, but not other receptor antagonists. In addition to inhibiting NMDA-evoked responses, SR 57227A also depressed significantly pharmacologically isolated, NMDA receptor-mediated, monosynaptic excitatory postsynaptic currents (EPSCs) elicited by electrical stimulation of the forceps minor; this inhibitory action was blocked by BRL 46470A but not other 5-HT receptor antagonists. Perfusion of Ca2+-free or low Ca2+ plus Cd2+ artificial cerebrospinal fluid prevented electrical stimulation-induced EPSCs, but did not affect the inhibitory action of 5-HT and SR 57227A. In conclusion, we demonstrate for the first time that 5-HT and SR 57227A interact with 5-HT3-like receptors to produce a direct inhibitory action on NMDA receptor-mediated response in pyramidal cells of the mPFC.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9635896     DOI: 10.1002/(SICI)1098-2396(199807)29:3<257::AID-SYN8>3.0.CO;2-5

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  6 in total

1.  A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia.

Authors:  Maryam Noroozian; Sina Ghasemi; Seyed-Mohammad-Reza Hosseini; Amirhossein Modabbernia; Mohammad-Reza Khodaie-Ardakani; Omid Mirshafiee; Mehdi Farokhnia; Masih Tajdini; Farzin Rezaei; Bahman Salehi; Mandana Ashrafi; Habibeh Yekehtaz; Mina Tabrizi; Shahin Akhondzadeh
Journal:  Psychopharmacology (Berl)       Date:  2013-03-21       Impact factor: 4.530

2.  The ascending median raphe projections are mainly glutamatergic in the mouse forebrain.

Authors:  András Szőnyi; Márton I Mayer; Csaba Cserép; Virág T Takács; Masahiko Watanabe; Tamás F Freund; Gábor Nyiri
Journal:  Brain Struct Funct       Date:  2014-11-09       Impact factor: 3.270

3.  Granisetron adjunct to fluvoxamine for moderate to severe obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial.

Authors:  Neda Askari; Mahdieh Moin; Mohammad Sanati; Masih Tajdini; Seyed-Mohammad-Reza Hosseini; Amirhossein Modabbernia; Babak Najand; Samrand Salimi; Mina Tabrizi; Mandana Ashrafi; Reza Hajiaghaee; Shahin Akhondzadeh
Journal:  CNS Drugs       Date:  2012-10-01       Impact factor: 6.497

Review 4.  Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction.

Authors:  Alan L Pehrson; Connie Sanchez
Journal:  CNS Spectr       Date:  2013-08-01       Impact factor: 3.790

5.  In vivo blockade of 5HT3 receptors in the infralimbic medial prefrontal cortex enhances fear extinction in a rat model of PTSD.

Authors:  Ahmad Mohammadi-Farani; Mahdi Taghadosi; Sara Raziee; Zahra Samimi
Journal:  Iran J Basic Med Sci       Date:  2021-06       Impact factor: 2.699

6.  Acute 5-HT7 receptor activation increases NMDA-evoked currents and differentially alters NMDA receptor subunit phosphorylation and trafficking in hippocampal neurons.

Authors:  Maryam S Vasefi; Kai Yang; Jerry Li; Jeff S Kruk; John J Heikkila; Michael F Jackson; John F MacDonald; Michael A Beazely
Journal:  Mol Brain       Date:  2013-05-14       Impact factor: 4.041

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.